<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956553</url>
  </required_header>
  <id_info>
    <org_study_id>HPV CSP01</org_study_id>
    <nct_id>NCT00956553</nct_id>
  </id_info>
  <brief_title>Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls</brief_title>
  <acronym>HPV CSP01</acronym>
  <official_title>A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV study to evaluate the body's immune response of participants to the&#xD;
      Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with&#xD;
      increased risk of cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study looks at possible cross reactivity between different HPV serotypes and both&#xD;
      peripheral antibodies and mucosally-secreted antibodies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45</measure>
    <time_frame>18 months from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine differences in vaccine formulation and their impact on cross protection.</measure>
    <time_frame>24 months from enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>Cervarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>Three doses of Cervarix at month 0, 1 and 6.</description>
    <arm_group_label>Cervarix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>Three doses of Gardasil at month 0, 1 and 6.</description>
    <arm_group_label>Gardasil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 13 and 15 years at the time of the first immunisation&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  No contraindications to vaccination as specified in the &quot;Green Book&quot; - Immunisation&#xD;
             Against Infectious Disease, HMSO.&#xD;
&#xD;
          -  Written informed consent obtained from parent or guardian of subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or become pregnant during the course of the trial (no contraindications to&#xD;
             vaccination for those taking the contraceptive pill).&#xD;
&#xD;
          -  Breast-feeding mothers&#xD;
&#xD;
          -  Allergic to vaccine components&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Public Health England</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Elizabeth Miller</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Health England</name>
      <address>
        <city>London</city>
        <zip>NW9 5HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28319456</url>
    <description>Published study results</description>
  </link>
  <results_reference>
    <citation>Haskins-Coulter T, Southern J, Andrews N, Miller E. Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females. Hum Vaccin Immunother. 2017 Jun 3;13(6):1-9. doi: 10.1080/21645515.2016.1277846. Epub 2017 Mar 20.</citation>
    <PMID>28319456</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>Cervical cancer vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

